Although it is normal for insurance providers to reject claims for off-label uses of medications, they seem to support approval of intranasal naloxone kits. State regulations regarding naloxone are changing each week, but in general many are lightening up “Good Samaritan” laws to protect first responders from liability, according to Dr. Fudin. 

TRENDING ON CPA: Equalizing The Pain Pendulum 

“Most states are easing up availability. Some allow pharmacists to dispense it without a prescription, whereas others are formulating plans for pharmacists to do this, but only after many hours of special certificate training,” Dr. Fudin said. 

Disclosures: Jeffrey Fudin, PharmD, FCCP, has worked as a consultant and is a member of speaker’s bureaus for AstraZeneca, Millennium Health, Zogenix, and Kaléo. He is also a stock shareholder for Remitigate.


  1. Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July 2010. Available at: Accessed August 20, 2015.
  2. Centers for Disease Control and Prevention. Injury prevention & control: prescription drug overdose. Available at: Accessed August 20, 2015.
  3. Committee on Advancing Pain Research, Care, and Education. Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC; The National Academies Press:2011.
  4. Kerr D, Kelly A-M, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104:2067-2074.
  5. Edwards ET, Edwards ES, Davis E, Mulcare M, Wiklund M, Kelley G. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. Pain Ther. 2015;4(1):89-105.

This article originally appeared on MPR